Table 3. Key prospective studies for transarterial chemoembolization with drug-eluting beads in metastatic colorectal cancer.
| Study (year) | Analysis | Regimen | Patients (n) | Ref. |
|---|---|---|---|---|
| DEB-TACE combined with first-line chemotherapy | ||||
| Martin et al. (2012) | Prospective | DEB-TACE (irinotecan) plus modified FOLFOX | 10 | [60] |
| DEB-TACE as salvage therapy in chemorefractory mCRC | ||||
| Martin et al. (2010) | Prospective | DEB-TACE (irinotecan) | 55 | [61] |
| Aliberti et al. (2011) | Prospective | DEB-TACE (irinotecan) | 82 | [62] |
| Fiorentini et al. (2012) | Prospective | DEB-TACE (irinotecan) vs FOLFIRI | 36 vs 38 | [63] |
DEB-TACE: Transarterial chemoembolization with drug-eluting beads; FOLFIRI: Irinotecan, 5-fluorouracil and leucovorin; FOLFOX: 5-fluorouracil, oxaliplatin and leucovorin; mCRC: Metastatic colorectal cancer.